Typical role: GLP-1s are currently best thought of as an adjunctan add-on while we await more trials and approvals
Hermanowicz, P., Sarna, M., Burda, K
A Phase 2 trial showed promise
One of their biggest advantages is their new Zepbound KwikPen for cash-pay patients
Regional Outlook and Growth Opportunities The market demonstrates strong regional growth dynamics: USA (18.2% CAGR): Leading adoption driven by GLP-1 therapy penetration and product innovation UK (16.4% CAGR): Growth through DTC nutrition brands and functional meal formats Germany (15.8% CAGR): High demand for premium, structured nutrition solutions Japan (15.1% CAGR): Convenience-led, portion-controlled innovation South Korea (14.7% CAGR): Growth in functional beverages and snack formats North America leads commercialization, while Europe and East Asia drive premiumization and format innovation
Kang reviews your imaging, health history, and goals during a consultation to help you decide if MUSE cell therapy and peptides are the right next step